The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

2.

Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.

3.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

4.

Next Day Mood Is Affected by Ability to Recover From Work.

5.

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot